CA3003213C - Polymorphs of acyl sulfonamides - Google Patents

Polymorphs of acyl sulfonamides Download PDF

Info

Publication number
CA3003213C
CA3003213C CA3003213A CA3003213A CA3003213C CA 3003213 C CA3003213 C CA 3003213C CA 3003213 A CA3003213 A CA 3003213A CA 3003213 A CA3003213 A CA 3003213A CA 3003213 C CA3003213 C CA 3003213C
Authority
CA
Canada
Prior art keywords
compound
acid
hiv
administration
polymorphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3003213A
Other languages
English (en)
French (fr)
Other versions
CA3003213A1 (en
Inventor
James Prentice Davidson
Michael Martin
Fei PANG
Margaret Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA3003213A1 publication Critical patent/CA3003213A1/en
Application granted granted Critical
Publication of CA3003213C publication Critical patent/CA3003213C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3003213A 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides Active CA3003213C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9536408P 2008-09-09 2008-09-09
US61/095,364 2008-09-09
CA2949912A CA2949912C (en) 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2949912A Division CA2949912C (en) 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides

Publications (2)

Publication Number Publication Date
CA3003213A1 CA3003213A1 (en) 2010-03-18
CA3003213C true CA3003213C (en) 2021-07-20

Family

ID=41664548

Family Applications (5)

Application Number Title Priority Date Filing Date
CA3003213A Active CA3003213C (en) 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides
CA2949912A Active CA2949912C (en) 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides
CA3086566A Active CA3086566C (en) 2008-09-09 2009-08-31 ACYLATE SULFONAMIDE POLYMORPHS
CA3059552A Active CA3059552C (en) 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides
CA2735192A Active CA2735192C (en) 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides

Family Applications After (4)

Application Number Title Priority Date Filing Date
CA2949912A Active CA2949912C (en) 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides
CA3086566A Active CA3086566C (en) 2008-09-09 2009-08-31 ACYLATE SULFONAMIDE POLYMORPHS
CA3059552A Active CA3059552C (en) 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides
CA2735192A Active CA2735192C (en) 2008-09-09 2009-08-31 Polymorphs of acyl sulfonamides

Country Status (16)

Country Link
US (1) US8063103B2 (https=)
EP (1) EP2334638B1 (https=)
JP (6) JP5989339B2 (https=)
KR (7) KR20180110237A (https=)
CN (1) CN102143943B (https=)
AU (1) AU2009290988B2 (https=)
BR (3) BR122021020474B1 (https=)
CA (5) CA3003213C (https=)
EA (1) EA019340B1 (https=)
ES (1) ES2706875T3 (https=)
IL (4) IL299322B2 (https=)
MX (1) MX2011002319A (https=)
PL (1) PL2334638T3 (https=)
TR (1) TR201818979T4 (https=)
UA (1) UA107561C2 (https=)
WO (1) WO2010028968A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2644156C1 (ru) 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
RU2665383C9 (ru) * 2017-06-22 2019-07-23 Общество с ограниченной ответственностью "Вириом" Фармацевтическая наносуспензия для терапии ВИЧ-инфекции
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
RU2716257C1 (ru) * 2019-04-30 2020-03-11 Андрей Александрович Иващенко Активный компонент, фармацевтическая композиция и лекарственный препарат для терапии ВИЧ и СПИДа
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21546A (id) * 1997-01-23 1999-06-24 Yamanouchi Pharmaceuticl Co Lt Turunan-turunan amida baru dan komposisi-komposisi obat darinya
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
DE602005017604D1 (de) * 2004-04-23 2009-12-24 Hoffmann La Roche Inhibitoren der nicht-nukleosid-inhibitoren der reversen transkriptase
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
JP4173909B1 (ja) * 2005-04-28 2008-10-29 ファイザー・リミテッド アミノ酸誘導体
WO2009018233A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
WO2007045573A1 (en) * 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
CA2716082A1 (en) * 2008-03-04 2009-02-23 F. Hoffmann-La Roche Ag Process for preparing concentrated aqueous micellar solutions

Also Published As

Publication number Publication date
IL299322B2 (en) 2024-10-01
JP2021176894A (ja) 2021-11-11
IL299322B1 (en) 2024-06-01
JP2018058862A (ja) 2018-04-12
CN102143943A (zh) 2011-08-03
CA2735192C (en) 2017-02-28
CN102143943B (zh) 2014-03-12
KR101678700B1 (ko) 2016-11-22
EA201100451A1 (ru) 2011-10-31
JP6450340B2 (ja) 2019-01-09
KR20110053234A (ko) 2011-05-19
CA2735192A1 (en) 2010-03-18
IL299322A (en) 2023-02-01
IL211353A0 (en) 2011-05-31
JP2012502075A (ja) 2012-01-26
AU2009290988B2 (en) 2016-01-28
AU2009290988A1 (en) 2010-03-18
JP2023082131A (ja) 2023-06-13
EP2334638B1 (en) 2018-11-21
JP2019194229A (ja) 2019-11-07
CA3059552A1 (en) 2010-03-18
MX2011002319A (es) 2011-04-05
KR20210108499A (ko) 2021-09-02
KR20160092049A (ko) 2016-08-03
ES2706875T3 (es) 2019-04-01
CA3003213A1 (en) 2010-03-18
BR122021020474B1 (pt) 2022-06-07
KR101822319B1 (ko) 2018-01-25
BR122021020475B1 (pt) 2022-06-07
JP5989339B2 (ja) 2016-09-07
KR20230113420A (ko) 2023-07-28
TR201818979T4 (tr) 2019-01-21
CA3086566A1 (en) 2010-03-18
KR102437499B1 (ko) 2022-08-29
IL264118A (en) 2019-02-28
CA3086566C (en) 2025-09-02
IL244350A0 (en) 2016-05-01
US20100063154A1 (en) 2010-03-11
CA2949912C (en) 2019-12-03
BRPI0918526A2 (pt) 2015-12-01
WO2010028968A2 (en) 2010-03-18
EP2334638A2 (en) 2011-06-22
KR102560207B1 (ko) 2023-07-27
KR20180110237A (ko) 2018-10-08
PL2334638T3 (pl) 2019-04-30
EA019340B1 (ru) 2014-02-28
WO2010028968A3 (en) 2010-06-10
IL211353A (en) 2016-04-21
KR20220120723A (ko) 2022-08-30
BRPI0918526B1 (pt) 2022-02-15
CA2949912A1 (en) 2010-03-18
KR20180001582A (ko) 2018-01-04
UA107561C2 (xx) 2015-01-26
CA3059552C (en) 2021-03-16
US8063103B2 (en) 2011-11-22
JP2016172741A (ja) 2016-09-29

Similar Documents

Publication Publication Date Title
JP2023082131A (ja) アシルスルホンアミドの多形体
CA2559552A1 (en) Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
US20100056535A1 (en) Inhibitors of HIV-1 reverse transcriptase

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180430

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250828